Can a new Israeli company really find a cure for cancer? Efranat just raised $4.5 million from people who think that it just might.
$4.5 million sounds like a bargain for the chance to cure one of the world’s most dreaded diseases.
Efranat Ltd. is developing an immunotherapy treatment approach for cancer, based on a glycoprotein named GcMAF (Globulin component Macrophage Activating Factor).
The product and treatment are based on Professor Nobuto Yamamoto’s innovative approach and extended research over the last 30 years. The concept underlying the innovative Yamamoto technology is to engage the body’s own natural immune system, and harness it to fight disease.
The company is currently performing trials ate the Sheba Medical Center in Tel Aviv with 40 patients who suffer from different types of cancer.
Efranat CEO Uri Yogev said, “We began by working with GcMAF from scratch. We developed a new, more stable, and patent-protected formula. We produced the material at the facilities of Kamada, which are FDA-approved. Efranat conducted spontaneous cancer trials on dogs (on dogs that developed cancer naturally, without it being induced), some of which recovered completely. A trial with 30-40 patients suffering from various types of cancer is currently being conducted at the Sheba Medical Center.”
“Yamanoto is not a young man; he is from the same generation as Shimon Peres. He researched the matter, then let it lie, in effect sitting on the patents for several years.”
“Because this is a molecule that appears naturally in the body, the patent does not involve the material; it refers only to the production process. It was therefore easy to bypass it, and it is easy for all sorts of people around the world to sell promises that Yamamoto himself did not make. For example, one doctor set up a company in Guernsey Island that markets containers allegedly containing the material. We bought one of his containers, and couldn’t find the molecule in it. We’re keeping our distance from these people. We just want to produce and test the material according to the rules.”